Figure 3
![Figure 3. WST-1 viability assay on PIPLC-treated EA.hy926 cells. Percentage of nonviable PIPLC-treated EA.hy926 cells among different disease entities (data are presented as mean with standard error of the mean [SEM]). aPIGN, atypical postinfectious glomerulonephritis; Ecu-aHUS, atypical hemolytic uremic syndrome treated with eculizumab; Stec-HUS: Shiga-toxin–associated hemolytic uremic syndrome.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/125/23/10.1182_blood-2015-02-629683/4/3637f3.jpeg?Expires=1743072131&Signature=nX8QdbREeuc8rTWJgeHZyBJ-D5i1nDqfl69G5JgRO~MGsUSlizAk7MhP9GAGHmMgJWwYUS6GEH~Pd-wTFqyakee0iM545UZ5ayY1ZkLQMszk05CvMaYgtkmqTfjPzt8zqXBHoEHGPTs4~49s0RfLwGcACzv04IikGISfrqQxnNHbOi-BEhVlXZQqbRefMixdXzOv-EwcuFPTp5d2cwXfyHU1rEZycSX40xkNyS1Pl0UOMv-uco6wj8RQ9Nzyz7jZ5j4rxen8yC6R4quSOg3C9TwPvvEh7OKvcDVrFTZXo5Ph92VndMtQHkDPGXZd-4BU13CstcI522Wz5~at-lBZcw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
WST-1 viability assay on PIPLC-treated EA.hy926 cells. Percentage of nonviable PIPLC-treated EA.hy926 cells among different disease entities (data are presented as mean with standard error of the mean [SEM]). aPIGN, atypical postinfectious glomerulonephritis; Ecu-aHUS, atypical hemolytic uremic syndrome treated with eculizumab; Stec-HUS: Shiga-toxin–associated hemolytic uremic syndrome.
